QCM
TVTX icon

Quantinno Capital Management’s Travere Therapeutics TVTX Stock Holding History

Quantinno Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.03M Buy
70,863
+2,546
+4% +$113K ﹤0.01% 1417
2026
Q1 		$2.03M Buy
68,317
+53,283
+354% +$1.59M ﹤0.01% 1621
2025
Q4 		$574K Buy
15,034
+1,660
+12% +$54K ﹤0.01% 2280
2025
Q3 		$320K Buy
13,374
+3
+0% +$56 ﹤0.01% 2409
2025
Q2 		$198K Buy
+13,371
New +$222K ﹤0.01% 2370

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quantinno Capital Management's TVTX Position: Q2 2026 in Review

Quantinno Capital Management increased its Travere Therapeutics (TVTX) stake by 3.7% in Q2 2026, buying an estimated $113K and bringing the position to 70,863 shares worth $4.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1417.

Quantinno Capital Management first reported a position in TVTX in Q2 2025 and has held it in 5 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Quantinno Capital Management held 70,863 shares of Travere Therapeutics worth $4.03M as of Q2 2026.
  • Quantinno Capital Management bought 2,546 Travere Therapeutics shares in Q2 2026, an estimated $113K.
  • Travere Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #1417 holding.
  • Quantinno Capital Management first reported a position in Travere Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.